Dendritic cells (DCs) are master regulators of the immune response and, because of their peculiar features in antigen acquisition, processing, and presentation, they play a critical role in activating an efficient antigenspecific T-lymphocyte response against tumors. However, the DC family is composed of different cell subsets, which may differently contribute to tumor-specific T-cell activation. In addition to the DC subset involved, the induction of a tumor-specific adaptive immune response is also dependent on DC interactions with other innate cell effectors, such as natural killer cells. The different modalities by which DCs can acquire tumor antigens also significantly affect antigen presentation because, in addition to the presentation of tumor antigens on MHC class II upon the classical exogenous antigen processing pathway, DCs are equipped to directly activate cytotoxic T cells via both cross-priming and cross-dressing. Here, the different forms of tumor antigen presentation by DCs are reviewed and discussed. We also discuss the ways in which this novel information could be exploited in the design of DC-based cancer vaccines.

Acquisition and presentation of tumor antigens by dendritic cells.

Bonaccorsi Irene
Co-primo
;
Campana Stefania
Co-primo
;
Guido Ferlazzo
Ultimo
2015-01-01

Abstract

Dendritic cells (DCs) are master regulators of the immune response and, because of their peculiar features in antigen acquisition, processing, and presentation, they play a critical role in activating an efficient antigenspecific T-lymphocyte response against tumors. However, the DC family is composed of different cell subsets, which may differently contribute to tumor-specific T-cell activation. In addition to the DC subset involved, the induction of a tumor-specific adaptive immune response is also dependent on DC interactions with other innate cell effectors, such as natural killer cells. The different modalities by which DCs can acquire tumor antigens also significantly affect antigen presentation because, in addition to the presentation of tumor antigens on MHC class II upon the classical exogenous antigen processing pathway, DCs are equipped to directly activate cytotoxic T cells via both cross-priming and cross-dressing. Here, the different forms of tumor antigen presentation by DCs are reviewed and discussed. We also discuss the ways in which this novel information could be exploited in the design of DC-based cancer vaccines.
2015
File in questo prodotto:
File Dimensione Formato  
Bonaccorsi et al., 2015c.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 633.94 kB
Formato Adobe PDF
633.94 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3124619
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact